Saturday, 31 October 2026European Markets

EBUSCO HOLDING Stock Was 11.63% Up On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with EBUSCO HOLDING (EBUS.AS) rising 11.63% to €7.87 on Tuesday while AEX-Index jumped 0.19% to €736.77.

EBUSCO HOLDING's last close was €7.05, 60.17% below its 52-week high of €17.70.

About EBUSCO HOLDING

Ebusco Holding N.V., together with its subsidiaries, develops, manufactures, and distributes zero emission buses, batteries, and charging systems in the Netherlands, Belgium, France, Germany, Norway, Switzerland, and Denmark. It also sells ancillary products and services; and provides electric vehicle ecosystem repair and maintenance services. Ebusco Holding N.V. was founded in 2010 and is headquartered in Deurne, the Netherlands.

Earnings Per Share

As for profitability, EBUSCO HOLDING has a trailing twelve months EPS of €-1.11.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -20.25%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EBUSCO HOLDING's stock is considered to be oversold (<=20).

Volume

Today's last reported volume for EBUSCO HOLDING is 893622 which is 411.47% above its average volume of 174715.

Revenue Growth

Year-on-year quarterly revenue growth grew by 12.5%, now sitting on 116.25M for the twelve trailing months.

More news about EBUSCO HOLDING (EBUS.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,514 source documents archived
Query this data → isubstrate.com